# AKT1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - AKT1 is a serine/threonine-protein kinase central to the PI3K signaling axis, regulating proliferation, survival, metabolism, angiogenesis, and motility, with dysregulation being a hallmark of numerous human malignancies. - The AKT1 gene, located at 14q32.33, encodes a 480-amino-acid protein with a Pleckstrin Homology (PH) domain for membrane recruitment and a kinase domain for catalytic activity, regulated by phosphorylation at Thr308 (by PDK1) and Ser473 (by mTORC2). - Pathogenic alterations include the recurrent somatic E17K mutation in the PH domain, which confers constitutive membrane recruitment and activation, driving oncogenesis in breast, colorectal, and ovarian cancers, and germline mutations causing rare overgrowth syndromes like Proteus syndrome. - AKT1 is a critical target for viral and bacterial pathogens, which hijack its signaling to promote replication and survival, and is a major therapeutic target, with ATP-competitive inhibitors like capivasertib (AZD5363) and allosteric inhibitors like miransertib (ARQ-092) demonstrating clinical utility. - Resistance to AKT inhibitors often involves upstream RTK activation, PTEN loss, or compensatory mTORC1 activation, necessitating combination strategies with other targeted agents or chemotherapy, with PIK3CA mutations, AKT1 mutations (E17K), and PTEN loss serving as predictive biomarkers. --- ## Executive Summary & Key Metadata The AKT1 gene encodes the serine/threonine-protein kinase AKT1 (also known as Protein Kinase B alpha, PKBα), a central node in the phosphoinositide 3-kinase (PI3K) signaling axis. AKT1 integrates extracellular growth factor signals to regulate a broad spectrum of cellular processes, including proliferation, survival, metabolism, angiogenesis, and motility. Dysregulation of AKT1—through activating mutations, gene amplification, or upstream pathway aberrations—is a hallmark of numerous human malignancies and rare overgrowth syndromes. This manual provides a comprehensive, biophysically grounded reference for AKT1, spanning its genomic architecture, three-dimensional protein structure, signaling networks, pathogenic mutations, pharmacogenomic targeting, and bioinformatic resources. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | AKT1 | | **UniProt Accession** | P31749 | | **Representative PDB ID** | true (e.g., 6HHF, 6S9Z, 3CQW) | | **Chromosomal Locus** | 14q32.33 (GRCh38: chr14:104,769,349-104,795,748) | | **Primary Molecular Function** | Serine/threonine-protein kinase; phosphorylates substrates on Ser/Thr residues within the motif RXRXX(S/T) | | **Disease & Pathology Associations** | Breast, colorectal, lung, ovarian, and prostate cancers; Proteus syndrome; Cowden syndrome-like phenotypes; AKT1-related megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome (MPPH) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Location and Gene Structure The human AKT1 gene is located on the long (q) arm of chromosome 14 at cytogenetic band 14q32.33. In the GRCh38 assembly, AKT1 spans approximately 26.4 kilobases (kb) of genomic DNA, from position 104,769,349 to 104,795,748 on the forward strand. The gene is composed of 14 canonical exons and 13 introns, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 14. The coding sequence (CDS) is 1,440 nucleotides in length, encoding a protein of 480 amino acids with a predicted molecular mass of ~55.7 kDa (UniProt P31749). The genomic organization of AKT1 is notable for its complex 5' untranslated region (UTR). The 5' UTR is encoded by a portion of exon 1 and is unusually long (~500 bp in some transcripts), containing multiple upstream open reading frames (uORFs) and a highly structured guanine-cytosine (GC)-rich region. These elements are critical for translational regulation, allowing AKT1 mRNA to be translationally silenced under basal conditions and rapidly mobilized upon growth factor stimulation. The 3' UTR, encoded by exon 14, is also extensive (~4 kb) and contains multiple AU-rich elements (AREs) and binding sites for microRNAs (e.g., miR-21, miR-155, miR-486), which modulate mRNA stability and translation. ### 1.2 Promoter Architecture and Transcriptional Regulation The AKT1 promoter lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island is a target for DNA methylation-mediated silencing. The core promoter is characterized by multiple Sp1 (Specificity Protein 1) binding sites, which are essential for basal transcription. Additionally, the promoter region contains consensus binding motifs for several inducible transcription factors, including: - **NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells):** NF-κB binding sites in the AKT1 promoter mediate transcriptional upregulation in response to inflammatory cytokines (e.g., TNF-α) and genotoxic stress. - **STAT3 (Signal Transducer and Activator of Transcription 3):** STAT3 directly binds the AKT1 promoter and drives its expression in response to IL-6 family cytokines, contributing to oncogenic feedback loops. - **c-Myc:** The c-Myc oncoprotein binds E-box elements within the AKT1 promoter, enhancing transcription in proliferating cells. - **p53:** Under conditions of DNA damage, p53 can repress AKT1 transcription via binding to a p53-responsive element in the promoter, providing a tumor-suppressive checkpoint. Enhancer elements regulating AKT1 expression are located both upstream and within intronic regions. Chromatin conformation capture (Hi-C) studies in ENCODE have identified a distal enhancer cluster ~50 kb upstream of the TSS that physically interacts with the AKT1 promoter in a cell-type-specific manner. This enhancer region is marked by H3K27ac (histone H3 lysine 27 acetylation) and is bound by pioneer transcription factors such as FOXA1 in hormone-responsive tissues. ### 1.3 Alternative Splicing and Isoforms Alternative splicing of AKT1 produces multiple transcript variants. The canonical transcript (ENST00000349310.9) encodes the full-length 480-amino-acid protein. However, several non-canonical splice variants have been characterized: - **AKT1_v2 (Δ4-5):** This variant skips exons 4 and 5, resulting in an in-frame deletion of 62 amino acids within the linker region between the pleckstrin homology (PH) domain and the kinase domain. This isoform exhibits reduced membrane-binding affinity and altered substrate specificity. - **AKT1_v3 (ΔExon 11):** Skipping of exon 11 introduces a premature stop codon, producing a truncated protein lacking the C-terminal hydrophobic motif. This isoform acts as a dominant-negative regulator, sequestering upstream activators. - **AKT1_v4 (Intronic Retention):** Retention of intron 7 leads to a frameshift and production of a short peptide that is subject to nonsense-mediated decay (NMD), representing a regulatory mechanism for controlling AKT1 protein levels. The expression of these splice variants is tissue-specific and dynamically regulated during development and oncogenesis. For instance, AKT1_v2 is overexpressed in a subset of glioblastomas, where it promotes resistance to PI3K inhibitors by maintaining constitutive kinase activity independent of PH-domain-mediated membrane recruitment. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The AKT1 protein is a modular kinase composed of three distinct functional domains, arranged from the N-terminus to the C-terminus: 1. **Pleckstrin Homology (PH) Domain (Residues 1–113):** The PH domain is a ~120-residue module that binds phosphoinositides, specifically phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2). This interaction is the primary mechanism for AKT1 recruitment to the plasma membrane. The PH domain consists of a seven-stranded β-sandwich (β1-β7) capped by a C-terminal α-helix. The phosphoinositide-binding pocket is formed by the β1-β2 and β3-β4 loops, which contain conserved basic residues (e.g., Lys14, Arg23, Arg25) that coordinate the phosphate groups of the inositol ring. A key structural feature is the "PH-domain conformational change" that occurs upon PIP3 binding, which exposes the activation loop (T-loop) for phosphorylation by upstream kinases. 2. **Kinase Domain (Residues 148–411):** The catalytic core adopts the canonical bi-lobed protein kinase fold. The N-terminal lobe (N-lobe) consists of a five-stranded β-sheet (β1-β5) and a single α-helix (αC). The C-terminal lobe (C-lobe) is predominantly α-helical and contains the catalytic loop (HRD motif, residues 292–294), the magnesium-binding loop (DFG motif, residues 292–294), and the activation loop (residues 292–294). The ATP-binding site is located in the deep cleft between the N- and C-lobes, with the adenine ring of ATP forming hydrogen bonds with the hinge region (residues 227–229). Key catalytic residues include Lys179 (which coordinates the α- and β-phosphates of ATP) and Asp292 (the catalytic base that accepts a proton from the substrate hydroxyl group). 3. **C-Terminal Regulatory Domain (Residues 412–480):** This domain contains two critical regulatory phosphorylation sites: Thr450 and Ser473. Thr450 is a constitutive phosphorylation site within a turn motif, which is phosphorylated by mTORC2 (mechanistic Target of Rapamycin Complex 2) and is required for proper protein folding and stability. Ser473 is located within a hydrophobic motif (F-X-X-F/Y-S/T-Y-F), which is the second mTORC2 phosphorylation site. Phosphorylation of Ser473 is essential for full AKT1 activation, as it stabilizes the active conformation of the kinase domain by interacting with a hydrophobic pocket on the N-lobe. ### 2.2 Structural Basis of Activation The activation of AKT1 is a multi-step process that involves dramatic conformational changes. In the basal state, the PH domain and the kinase domain engage in an intramolecular interaction that locks the kinase in an inactive "PH-in" conformation. In this state, the activation loop is partially disordered, and the ATP-binding site is occluded. Upon growth factor stimulation, PIP3 accumulates at the plasma membrane. The PH domain binds PIP3, which induces a conformational rearrangement that releases the kinase domain. This "PH-out" conformation allows the activation loop to be phosphorylated by PDK1 (3-Phosphoinositide-Dependent Protein Kinase 1) at Thr308. Phosphorylation of Thr308 stabilizes the activation loop in an extended, catalytically competent conformation, resulting in partial kinase activity. However, full activation requires subsequent phosphorylation of Ser473 by mTORC2. The phosphorylation of Ser473 promotes a final conformational change that locks the kinase domain into a fully active state, increasing catalytic activity by 10- to 100-fold. ### 2.3 Key Structural Motifs and Binding Pockets - **ATP-Binding Pocket:** The ATP-binding site is a druggable target for small-molecule inhibitors. It is characterized by a hydrophobic pocket lined by residues Leu156, Val164, Ala177, and Met227. The hinge region (Glu228–Ala230) forms critical hydrogen bonds with the adenine ring of ATP. Selectivity between AKT isoforms (AKT1 vs. AKT2 vs. AKT3) can be achieved by targeting residues that differ in the ATP-binding site, such as the gatekeeper residue (Thr211 in AKT1 vs. Met211 in AKT2). - **Substrate-Binding Groove:** The substrate-binding site is located on the C-lobe, adjacent to the catalytic loop. AKT1 recognizes substrates with the consensus sequence R-X-R-X-X-S/T-B (where B is a bulky hydrophobic residue). The P+1 pocket, which accommodates the residue C-terminal to the phospho-acceptor, is formed by residues Phe438 and Phe442. - **Allosteric Binding Pocket:** A second, allosteric binding site exists at the interface between the PH domain and the kinase domain. This pocket is only accessible in the inactive "PH-in" conformation. Allosteric inhibitors (e.g., MK-2206) bind this pocket and stabilize the inactive state, preventing membrane recruitment and phosphorylation. > **Interactive 3D Protein Visualizer Callout** > > Explore the full three-dimensional architecture of AKT1, including the PH domain, kinase domain, and regulatory motifs, using our interactive molecular graphics tool. Load the experimentally determined structure (PDB: true) to visualize key residues, ligand binding sites, and conformational states. > > [**Interactive 3D Protein Visualizer: Load AKT1 (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=P31749) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The PI3K/AKT/mTOR Signaling Axis AKT1 is the central serine/threonine kinase in the PI3K/AKT/mTOR signaling pathway, which is one of the most frequently dysregulated pathways in human cancer. The pathway is initiated by the binding of extracellular growth factors (e.g., EGF, IGF-1, PDGF) to receptor tyrosine kinases (RTKs) at the cell surface. Ligand binding induces RTK dimerization and autophosphorylation on tyrosine residues, creating docking sites for the p85 regulatory subunit of PI3K. PI3K is recruited to the membrane and catalyzes the conversion of phosphatidylinositol (4,5)-bisphosphate (PIP2) to PIP3. The accumulation of PIP3 at the plasma membrane recruits AKT1 via its PH domain. Once membrane-bound, AKT1 is phosphorylated at Thr308 by PDK1, which is also recruited to the membrane via its PH domain. Full activation is achieved when mTORC2 phosphorylates AKT1 at Ser473. The tumor suppressor PTEN (Phosphatase and Tensin Homolog) negatively regulates this pathway by dephosphorylating PIP3 back to PIP2, thereby limiting AKT1 activation. ### 3.2 Downstream Substrates and Effector Networks Once activated, AKT1 phosphorylates a vast array of downstream substrates (>100 identified), controlling diverse cellular processes. Key substrates and their functional consequences include: - **Cell Survival and Apoptosis:** - **BAD (BCL2 Associated Agonist of Cell Death):** AKT1 phosphorylates BAD at Ser136, promoting its sequestration by 14-3-3 proteins and preventing it from inhibiting anti-apoptotic BCL-2 family members. - **Caspase-9:** AKT1 phosphorylates pro-caspase-9 at Ser196, inhibiting its proteolytic activation and thus blocking the intrinsic apoptosis pathway. - **MDM2 (Mouse Double Minute 2):** AKT1 phosphorylates MDM2 at Ser166 and Ser186, promoting its nuclear translocation and enhancing its E3 ubiquitin ligase activity towards p53, leading to p53 degradation. - **Cell Cycle Progression:** - **CDK Inhibitors:** AKT1 phosphorylates p21 (CDKN1A) at Thr145 and p27 (CDKN1B) at Thr157, causing their cytoplasmic retention and preventing them from inhibiting cyclin-CDK complexes in the nucleus. - **Cyclin D1:** AKT1 indirectly promotes Cyclin D1 expression by phosphorylating and inactivating GSK3β (Glycogen Synthase Kinase 3 Beta), which normally targets Cyclin D1 for proteasomal degradation. - **Metabolism:** - **GSK3β:** AKT1 phosphorylates GSK3β at Ser9, inhibiting its kinase activity. This promotes glycogen synthesis and prevents β-catenin degradation, leading to activation of Wnt target genes. - **FOXO Transcription Factors:** AKT1 phosphorylates FOXO1, FOXO3a, and FOXO4 at multiple sites (e.g., Thr24, Ser256, Ser319), creating 14-3-3 binding sites that export FOXO proteins from the nucleus, thereby inhibiting the transcription of pro-apoptotic and metabolic genes. - **TSC2 (Tuberous Sclerosis Complex 2):** AKT1 phosphorylates TSC2 at multiple sites, inhibiting the TSC1/TSC2 complex. This relieves the inhibition of mTORC1, promoting protein synthesis and cell growth. - **Angiogenesis and Cell Motility:** - **eNOS (Endothelial Nitric Oxide Synthase):** AKT1 phosphorylates eNOS at Ser1177, increasing nitric oxide production and promoting angiogenesis. - **PAK1 (P21-Activated Kinase 1):** AKT1 phosphorylates PAK1 at Ser21, promoting cell motility and invasion. ### 3.3 Regulatory Feedback Loops AKT1 signaling is tightly regulated by multiple negative feedback loops that prevent hyperactivation: 1. **mTORC1-S6K1-IRS1 Feedback Loop:** Activated mTORC1 phosphorylates S6K1, which in turn phosphorylates IRS1 (Insulin Receptor Substrate 1) at multiple serine residues. This phosphorylation targets IRS1 for proteasomal degradation and reduces its ability to couple RTKs to PI3K, thereby attenuating upstream signaling. 2. **AKT1-Dependent PTEN Regulation:** AKT1 can phosphorylate PTEN at Ser380, which stabilizes the PTEN protein but reduces its phosphatase activity. This creates a local positive feedback loop that can amplify AKT1 signaling. 3. **PHLPP-Mediated Dephosphorylation:** The PH domain Leucine-rich repeat Protein Phosphatase (PHLPP1/2) directly dephosphorylates AKT1 at Ser473, terminating its activity. PHLPP expression is frequently lost in cancer, contributing to sustained AKT1 activation. ### 3.4 Protein-Protein Interaction Networks AKT1 participates in a dense network of protein-protein interactions (PPIs) that extend beyond its canonical substrates. According to BioGRID and STRING databases, AKT1 has >500 documented physical interactors. Key interaction partners include: - **Chaperones:** HSP90 (Heat Shock Protein 90) and CDC37 bind to AKT1 and stabilize its kinase domain, protecting it from proteasomal degradation. Inhibition of HSP90 leads to rapid AKT1 degradation. - **Scaffolding Proteins:** 14-3-3 proteins bind to phosphorylated AKT1, modulating its subcellular localization and activity. - **Phosphatases:** PP2A (Protein Phosphatase 2A) dephosphorylates Thr308, while PHLPP dephosphorylates Ser473. - **Kinases:** PDK1 and mTORC2 are the primary upstream kinases, but AKT1 also interacts with IKKα (IκB Kinase Alpha) and TBK1 (TANK-Binding Kinase 1) in specific contexts. ```mermaid sequenceDiagram participant RTK as "Receptor Tyrosine Kinase" participant PI3K as "PI3K (p85/p110)" participant PIP2 as "PIP2" participant PIP3 as "PIP3" participant PTEN as "PTEN" participant AKT1 as "AKT1 (inactive)" participant PDK1 as "PDK1" participant mTORC2 as "mTORC2" participant AKT1_active as "AKT1 (active)" participant Substrates as "Downstream Substrates (BAD, FOXO, GSK3β, TSC2)" RTK->>PI3K: Ligand binding & RTK autophosphorylation PI3K->>PIP2: Phosphorylates PIP2->>PIP3: Converts to PIP3->>AKT1: Recruits via PH domain PTEN-->>PIP3: Dephosphorylates (negative regulation) AKT1->>PDK1: Thr308 phosphorylation AKT1->>mTORC2: Ser473 phosphorylation PDK1->>AKT1_active: Activates mTORC2->>AKT1_active: Fully activates AKT1_active->>Substrates: Phosphorylates Substrates-->>AKT1_active: Feedback loops (e.g., mTORC1-S6K1-IRS1) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 The E17K Activating Mutation The most well-characterized somatic mutation in AKT1 is a missense mutation at codon 17, resulting in a glutamic acid to lysine substitution (c.49G>A; p.Glu17Lys, commonly abbreviated as E17K). This mutation is located in the phosphoinositide-binding pocket of the PH domain. Structural and biochemical studies have shown that the E17K mutation creates a new salt bridge with the 3'-phosphate of PIP3, increasing the affinity of the PH domain for phosphoinositides by approximately 7-fold. This enhanced membrane binding leads to constitutive, ligand-independent activation of AKT1, as the kinase is constitutively recruited to the plasma membrane where it can be phosphorylated by PDK1 and mTORC2. The E17K mutation is an oncogenic driver in multiple cancer types: - **Breast Cancer:** E17K is found in ~2-4% of breast cancers, particularly in hormone receptor-positive (ER+/HER2-) tumors. It is mutually exclusive with PIK3CA mutations, suggesting functional redundancy. - **Colorectal Cancer:** E17K is present in ~2% of colorectal cancers and is associated with resistance to EGFR inhibitors (cetuximab). - **Prostate Cancer:** E17K is found in a small subset of prostate cancers and is associated with poor prognosis. - **Ovarian Cancer:** E17K is detected in ~3% of ovarian cancers, predominantly in the endometrioid subtype. ### 4.2 Other Recurrent Somatic Mutations Beyond E17K, several other recurrent somatic mutations have been identified in AKT1, although at lower frequencies: - **Q17K (p.Gln17Lys):** A rare mutation at the same codon, also resulting in constitutive activation. - **L52R (p.Leu52Arg):** Located in the PH domain, this mutation is predicted to disrupt the intramolecular interaction between the PH and kinase domains, favoring the active conformation. - **K179N (p.Lys179Asn):** Located in the ATP-binding site, this mutation is predicted to alter ATP binding affinity and has been observed in a few cases of lung cancer. - **D323Y (p.Asp323Tyr):** Located in the activation loop, this mutation may stabilize the active conformation. ### 4.3 Germline Mutations and Rare Diseases Germline mutations in AKT1 are rare but cause distinct clinical syndromes: - **Proteus Syndrome:** This is a rare, mosaic overgrowth disorder characterized by asymmetric, disproportionate overgrowth of the bones, skin, and other tissues. It is caused by somatic activating mutations in AKT1, most commonly E17K, occurring during embryogenesis. The mosaic nature of the mutation explains the asymmetric and patchy distribution of overgrowth. - **AKT1-Related Megalencephaly-Polymicrogyria-Polydactyly-Hydrocephalus (MPPH) Syndrome:** Germline or mosaic activating mutations in AKT1 (and AKT3) cause this neurodevelopmental disorder characterized by macrocephaly, cortical malformations (polymicrogyria), and hydrocephalus. - **Cowden Syndrome-Like Phenotype:** Some patients with germline AKT1 mutations (e.g., E17K) present with features resembling Cowden syndrome (PTEN hamartoma tumor syndrome), including macrocephaly, mucocutaneous lesions, and increased cancer risk. ### 4.4 ClinVar Classifications and Pathogenicity ClinVar contains numerous entries for AKT1 variants. The E17K variant is classified as "Pathogenic" for both somatic cancer and Proteus syndrome. Other variants are classified as "Likely Pathogenic" or "Variant of Uncertain Significance (VUS)" based on population frequency, computational prediction, and functional assays. The American College of Medical Genetics and Genomics (ACMG) guidelines are used to classify these variants, with criteria including: - **PS1 (Pathogenic Strong 1):** Same amino acid change as an established pathogenic variant. - **PM1 (Pathogenic Moderate 1):** Located in a mutational hotspot or critical functional domain. - **PM2 (Pathogenic Moderate 2):** Absent from large population databases (e.g., gnomAD). - **PP3 (Pathogenic Supporting 3):** Multiple computational algorithms predict a deleterious effect. --- ## 5. Host-Pathogen & Viral Interactions AKT1 is a critical target for manipulation by various pathogens, which have evolved sophisticated mechanisms to hijack the PI3K/AKT pathway to promote their own replication, survival, and dissemination. ### 5.1 Viral Oncoproteins - **Hepatitis B Virus (HBV) HBx Protein:** The HBx protein of HBV activates AKT1 through multiple mechanisms. HBx can bind to the p85 regulatory subunit of PI3K, enhancing its activity and promoting PIP3 production. Additionally, HBx can activate Src family kinases, which indirectly activate PI3K. This sustained AKT1 activation contributes to HBV-induced hepatocarcinogenesis. - **Human Papillomavirus (HPV) E6 and E7:** The E6 oncoprotein of high-risk HPV types (e.g., HPV-16, HPV-18) can bind to and activate AKT1. E6 also promotes the degradation of p53, which normally represses AKT1 transcription. The E7 oncoprotein can activate AKT1 by binding to the retinoblastoma protein (pRb), leading to E2F-mediated transcription of AKT1. - **Epstein-Barr Virus (EBV) LMP1 and LMP2A:** The latent membrane proteins (LMPs) of EBV are constitutively active signaling molecules that mimic activated growth factor receptors. LMP1 activates the PI3K/AKT pathway via its C-terminal activating region (CTAR), while LMP2A provides a B-cell receptor (BCR)-like signal that activates PI3K. This is critical for EBV-driven B-cell lymphomas. - **Kaposi's Sarcoma-Associated Herpesvirus (KSHV) vGPCR:** The viral G protein-coupled receptor (vGPCR) encoded by KSHV is a constitutively active receptor that signals through PI3K to activate AKT1, promoting the proliferation of Kaposi's sarcoma spindle cells. ### 5.2 Bacterial Effectors - **Salmonella enterica SopB:** The SopB effector protein is a phosphoinositide phosphatase that is translocated into host cells via the type III secretion system. SopB dephosphorylates PIP2 to generate PI(3,4)P2, which recruits AKT1 to the membrane and activates it. This promotes host cell survival and facilitates bacterial invasion. - **Shigella flexneri IpgD:** Similar to SopB, IpgD is a phosphoinositide 4-phosphatase that generates PI(5)P and activates AKT1, promoting host cell survival during infection. - **Helicobacter pylori CagA:** The CagA oncoprotein is delivered into gastric epithelial cells via the type IV secretion system. CagA can bind to and activate PI3K, leading to AKT1 activation. This contributes to gastric carcinogenesis. ### 5.3 Viral Immune Evasion Several viruses activate AKT1 to evade the host immune response. For example, the NS1 protein of influenza A virus activates the PI3K/AKT pathway to delay apoptosis of infected cells, allowing more time for viral replication. Similarly, the Nef protein of HIV-1 activates AKT1 to promote survival of infected T cells and to modulate the expression of cell surface molecules involved in immune recognition. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors AKT1 is a high-priority therapeutic target in oncology, and significant efforts have been directed towards developing small-molecule inhibitors. These inhibitors can be broadly classified into ATP-competitive, allosteric, and PH-domain-targeting agents. ### 6.1 ATP-Competitive Inhibitors ATP-competitive inhibitors bind to the ATP-binding pocket of the kinase domain, preventing ATP from binding. These inhibitors are generally pan-AKT isoform inhibitors, as the ATP-binding site is highly conserved across AKT1, AKT2, and AKT3. - **Capivasertib (AZD5363):** This is an orally bioavailable, potent, and selective ATP-competitive inhibitor of all three AKT isoforms. It has shown significant clinical activity in breast cancer, particularly in tumors with PIK3CA/AKT1/PTEN alterations. In the phase III CAPItello-291 trial, capivasertib in combination with fulvestrant significantly improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer. It received FDA approval in November 2023. - **Ipatasertib (GDC-0068):** This is another potent, selective ATP-competitive AKT inhibitor. It has been evaluated in multiple phase III trials, including the IPATunity130 trial in triple-negative breast cancer (TNBC). While it showed activity in biomarker-selected populations, the overall results have been mixed. - **Uprosertib (GSK2141795):** This inhibitor has been evaluated in combination with other agents (e.g., trametinib) in clinical trials for various solid tumors. ### 6.2 Allosteric Inhibitors Allosteric inhibitors bind to a pocket at the interface between the PH domain and the kinase domain, stabilizing the inactive "PH-in" conformation. These inhibitors are highly isoform-selective and do not compete with ATP. - **MK-2206:** This is a highly selective allosteric inhibitor of AKT1 and AKT2. It has been evaluated in numerous clinical trials, but its development has been hampered by poor oral bioavailability and dose-limiting skin rash. It is no longer in active clinical development. - **ARQ-092 (Miransertib):** This is a potent allosteric inhibitor of AKT1/2/3. It has shown particular promise in the treatment of Proteus syndrome, where it has demonstrated clinical benefit in reducing overgrowth. It is also being evaluated in cancer clinical trials. ### 6.3 PH-Domain-Targeting Agents These agents disrupt the interaction between the PH domain and PIP3, preventing membrane recruitment. - **Perifosine (KRX-0401):** This is an alkylphospholipid that interferes with AKT1 membrane localization. It has been evaluated in clinical trials for multiple myeloma and colorectal cancer, but its efficacy has been limited. ### 6.4 Combination Strategies and Resistance Mechanisms Resistance to AKT inhibitors is a major clinical challenge. Common resistance mechanisms include: - **Upstream RTK Activation:** Cancer cells can upregulate RTKs (e.g., HER2, IGF-1R) to reactivate PI3K signaling. - **PTEN Loss:** Loss of PTEN leads to sustained PIP3 production, which can overcome the effects of AKT inhibition. - **mTORC1 Activation:** In some contexts, AKT inhibition leads to a compensatory activation of mTORC1, promoting cell survival. To overcome resistance, combination strategies are being explored, including: - **AKT + mTOR Inhibitors:** Dual inhibition of AKT and mTORC1/2 (e.g., capivasertib + everolimus) can block both arms of the pathway. - **AKT + MEK Inhibitors:** Co-targeting the RAS/MEK/ERK pathway, which is often co-activated with PI3K/AKT, can be synergistic. - **AKT + CDK4/6 Inhibitors:** Combining AKT inhibitors with CDK4/6 inhibitors (e.g., palbociclib) has shown promise in preclinical models of breast cancer. ### 6.5 Pharmacogenomic Biomarkers Predictive biomarkers for AKT inhibitor response include: - **PIK3CA Mutations:** Activating mutations in PIK3CA (e.g., H1047R, E545K) are the most common biomarkers for AKT inhibitor sensitivity. - **AKT1 Mutations:** The E17K mutation is a strong predictor of response to AKT inhibitors. - **PTEN Loss:** Loss of PTEN expression (by IHC or genomic deletion) is associated with response to AKT inhibitors, although the predictive value is less robust than PIK3CA/AKT1 mutations. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of key bioinformatic resources and database accessions for AKT1. | **Database** | **Identifier** | **URL** | | :--- | :--- | :--- | | **NCBI Gene** | 207 | [https://www.ncbi.nlm.nih.gov/gene/207](https://www.ncbi.nlm.nih.gov/gene/207) | | **Ensembl** | ENSG00000142208 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142208](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142208) | | **UniProt** | P31749 | [https://www.uniprot.org/uniprotkb/P31749/entry](https://www.uniprot.org/uniprotkb/P31749/entry) | | **RCSB PDB** | 6HHF, 6S9Z, 3CQW | [https://www.rcsb.org/search?q=AKT1](https://www.rcsb.org/search?q=AKT1) | | **OMIM** | 164730 | [https://www.omim.org/entry/164730](https://www.omim.org/entry/164730) | | **ClinVar** | Gene: AKT1 | [https://www.ncbi.nlm.nih.gov/clinvar/?term=AKT1%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=AKT1%5Bgene%5D) | | **COSMIC** | AKT1 | [https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKT1](https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKT1) | | **STRING** | P31749 | [https://string-db.org/network/P31749](https://string-db.org/network/P31749) | | **BioGRID** | 106678 | [https://thebiogrid.org/106678](https://thebiogrid.org/106678) | | **PhosphoSitePlus** | AKT1 | [https://www.phosphosite.org/proteinAction.action?id=1271](https://www.phosphosite.org/proteinAction.action?id=1271) | | **Gene Ontology (GO)** | GO:0004672, GO:0004674, GO:0005524, GO:0046777 | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) | | **Human Protein Atlas** | ENSG00000142208 | [https://www.proteinatlas.org/ENSG00000142208-AKT1](https://www.proteinatlas.org/ENSG00000142208-AKT1) | | **GDC (Genomic Data Commons)** | AKT1 | [https://portal.gdc.cancer.gov/genes/ENSG00000142208](https://portal.gdc.cancer.gov/genes/ENSG00000142208) | **Key Gene Ontology (GO) Terms:** - **Molecular Function:** - GO:0004672 – Protein kinase activity - GO:0004674 – Serine/threonine kinase activity - GO:0005524 – ATP binding - GO:0046777 – Protein autophosphorylation - GO:0031625 – Ubiquitin protein ligase binding - **Biological Process:** - GO:0006915 – Apoptotic process - GO:0008283 – Cell population proliferation - GO:0006468 – Protein phosphorylation - GO:0043066 – Negative regulation of apoptotic process - GO:0016310 – Phosphorylation - **Cellular Component:** - GO:0005737 – Cytoplasm - GO:0005634 – Nucleus - GO:0005886 – Plasma membrane - GO:0005829 – Cytosol --- ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway) ## References 1. Manning, B. D., & Toker, A. (2017). AKT/PKB Signaling: Navigating the Network. *Cell*, 169(3), 381–405. [https://doi.org/10.1016/j.cell.2017.04.001](https://doi.org/10.1016/j.cell.2017.04.001) 2. Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., ... & Thomas, R. K. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature*, 448(7152), 439–444. [https://doi.org/10.1038/nature05933](https://doi.org/10.1038/nature05933) 3. Lindhurst, L. E., Tapper, J. K., & Biesecker, L. G.